Hexarelin

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a). It is considered one of the strongest GH secretagogues available, producing substantial GH elevation. Developed by Mediolanum Farmaceutici, Hexarelin has been the subject of numerous clinical trials investigating its effects on GH release and cardiovascular function.

Beyond its GH-releasing properties, Hexarelin has demonstrated unique cardioprotective effects that appear to be independent of growth hormone elevation. It binds to a specific cardiac receptor (CD36) and has been shown to protect against cardiac ischemia, reduce fibrosis, and improve left ventricular function in animal models. This dual mechanism makes it particularly interesting from a research perspective.

Clinical studies have confirmed Hexarelin's potent GH-releasing activity, though tolerance can develop with chronic use more rapidly than with other secretagogues. Research has demonstrated peak GH levels 15-20 minutes after administration, with effects on body composition, bone density, and cardiac function. Its cardioprotective profile has generated significant research interest beyond the GH secretagogue space.